Therapeutic mechanism of Curcuma aromatica Salisb. rhizome against coronary heart disease based on integrated network pharmacology, pharmacological evaluation and lipidomics

Abstract

Curcuma aromatica Salisb. rhizome (CASR) has multifunctional characteristics worldwide and a long history of use as a botanical drug with. Currently, it is often used clinically to treat coronary heart disease (CHD) caused by blood stasis syndrome. However, the therapeutic mechanism of CASR in the treatment of CHD remains poorly understood. In study, the main chemical constituents of CASR were analyzed using UPLC-Q-TOF-MS/MS. Then, its potential therapeutic mechanism against CHD was predicted. Subsequently, pharmacological evaluation was performed using CHD rat model. Finally, a lipidomics approach was applied to explore the different lipid metabolites to verify the regulation of CASR on lipid metabolism disorders in CHD. A total of 35 compounds was identified from CASR. Seventeen active components and 51 potential targets related to CHD were screened by network pharmacology, involving 13 key pathways. In vivo experiments showed that CASR could significantly improve myocardial infarction, blood stasis, and blood lipid levels and regulate the PI3K/AKT/mTOR signaling pathway in CHD rats. Lipidomics further showed that CASR could regulate abnormal sphingolipid, glycerophospholipid, and glycerolipid metabolism in CHD rats. The therapeutic mechanism of CASR against CHD was initially elucidated and included the regulation of lipid metabolism. Its effects may be attributed to active ingredients, such as curzerene, isoprocurcumenol, and (+)-curcumenol. This study reveals the characteristics of multi-component and multi-pathway of CASR in the treatment of CHD, which provides a basis for the follow-up development and utilization of CASR.

The therapeutic mechanism of Curcumae Radix against primary dysmenorrea based on 5-HTR/Ca2+/MAPK and fatty acids metabolomics

“…This result is consistent with reports of its low oral bioavailability, which may be related to the poor solubility of curcumin components in gastrointestinal fluids or their rapid degradation at intestinal pH ( Zhu et al, 2022 ). These results are similar to those reported in previous studies ( Tong et al, 2021 ; Fei et al, 2022 ). To understand the process of action of these components in PD rats, the above components were predicted using network pharmacology.…”

“…The sample solutions of serum were prepared according to a previously established method ( Fei et al, 2022 ; Qin et al, 2022 ). In addition, quality control samples were prepared simultaneously to ensure the suitability of the method and system.…”

“…The experimental method for serum non-targeted metabolomics was the same as the above-mentioned serum composition method ( Fei et al, 2022 ). The One-MAP cloud platform was used to analyze the of each group (NC groups, M groups, and CW-H groups) serum mass spectrometry data and to identify the differential metabolites among the serum samples, which were compared with the standard secondary mass spectrometry data from the KEGG, HMDB, METLIN, and other compound databases as well as relevant literature.…”

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

“…Due to the elevated risk of mortality with these diseases, there is a need for strategies in its identification, prevention, and treatment within healthcare. In 2022, as evidenced in Figure 5, the bulk of research articles focussed on related diseases: CVD, 232–255 diabetes, 166,233,249,250,256–278 liver disease, 51,279–293 MetS 277,294,295 and obesity 277,295–305 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms “lipidomics” AND “clinic*” on 15 th December 2022 …”